Premium
CONMED Corporation (CNMD)
NYSE
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Mr. David M. BronsonIndependent Director | 668,00 | 0,00 | Derivative Exercise and Retained Stock | - | 17,91k | 3,87% |
| 2026-06-02 | Ms. Laverne H. CouncilIndependent Chairman of the Board | 668,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,72k | 16,50% |
| 2026-06-02 | Mr. Charles M. FarkasIndependent Director | 668,00 | 0,00 | Derivative Exercise and Retained Stock | - | 15,53k | 4,50% |
| 2026-06-02 | Mr. Mark Bradley KayeIndependent Director | 668,00 | 0,00 | Derivative Exercise and Retained Stock | - | 820,00 | 439,47% |
| 2026-06-02 | Ms. Barbara J. SchwarzentraubIndependent Director | 668,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,45k | 11,55% |
| 2026-03-06 | Mr. Brent LalomiaExec. VP of Regulatory Affairs, Quality Assurance, Clinical Affairs, Commercial Operations & IT | 49,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,04k | 4,94% |
| 2026-03-06 | Mr. Brent LalomiaExec. VP of Regulatory Affairs, Quality Assurance, Clinical Affairs, Commercial Operations & IT | -26,00 | 1,04k | Derivative Exercise and Sale | 39,90 | 1,04k | - |
| 2026-02-24 | Mr. Mark Bradley KayeIndependent Director | 152,00 | 0,00 | Derivative Exercise and Retained Stock | - | 152,00 | - |
| 2025-11-21 | Mr. Richard GlazeChief Information Officer | -257,00 | 10,59k | Vente | 41,21 | 0,00 | -100,00% |
| 2025-11-20 | Mr. Richard GlazeChief Information Officer | 257,00 | 0,00 | Derivative Exercise and Retained Stock | - | 257,00 | - |
| 2025-11-20 | Mr. Richard GlazeChief Information Officer | -118,00 | 4,79k | Derivative Exercise and Sale | 40,63 | 257,00 | - |
| 2025-11-06 | Mr. Todd W. GarnerAdvisor | -3,50k | 150,50k | Vente | 43,00 | 1,84k | -65,59% |
| 2025-11-04 | Ms. Hollie K. FoustExec. VP, General Counsel & Corporate Secretary | 2,89k | 0,00 | Derivative Exercise and Retained Stock | - | 2,89k | - |
| 2025-11-04 | Ms. Hollie K. FoustExec. VP, General Counsel & Corporate Secretary | -1,11k | 50,92k | Derivative Exercise and Sale | 45,71 | 2,89k | - |
| 2025-10-31 | Mr. Todd W. GarnerAdvisor | 5,34k | 0,00 | Derivative Exercise and Retained Stock | - | 5,34k | - |
| 2025-10-31 | Mr. Todd W. GarnerAdvisor | -2,16k | 95,22k | Derivative Exercise and Sale | 44,00 | 5,34k | - |
| 2025-09-12 | Mr. Charles M. FarkasIndependent Director | -2,00k | 107,05k | Vente | 53,51 - 53,54 | 14,86k | -11,86% |
| 2025-08-07 | Mr. Todd W. GarnerAdvisor | -598,00 | 31,37k | Vente | 52,45 | 0,00 | -100,00% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
